PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32049985-2	2020	NIS expression in thyroid cancer (TC) cells allows the use of radioactive iodine (RAI) as a diagnostic and therapeutic tool, being RAI therapy the systemic treatment of choice for metastatic disease.	Insulin, Short-Acting	82-85	solute carrier family 5 member 5	Homo sapiens	0-3	
32049985-2	2020	NIS expression in thyroid cancer (TC) cells allows the use of radioactive iodine (RAI) as a diagnostic and therapeutic tool, being RAI therapy the systemic treatment of choice for metastatic disease.	Insulin, Short-Acting	131-134	solute carrier family 5 member 5	Homo sapiens	0-3	
30932012-1	2019	Sufficient thyroid iodine uptake is needed to ensure effective radioactive iodine (RAI) treatment, which is mediated by the sodium-iodide symporter (NIS).	Insulin, Short-Acting	83-86	solute carrier family 5 member 5	Homo sapiens	149-152	
26770393-1	2015	CONTEXT: As many studies proved that sodium iodide symporter (NIS) plays a key role in radioactive iodide (RAI) therapy of thyroid cancer, however, a growing number of studies suggests that part of differentiated thyroid carcinomas (DTC) with overexpression of NIS are insensitive to RAI well.	Insulin, Short-Acting	107-110	solute carrier family 5 member 5	Homo sapiens	62-65	
26770393-1	2015	CONTEXT: As many studies proved that sodium iodide symporter (NIS) plays a key role in radioactive iodide (RAI) therapy of thyroid cancer, however, a growing number of studies suggests that part of differentiated thyroid carcinomas (DTC) with overexpression of NIS are insensitive to RAI well.	Insulin, Short-Acting	284-287	solute carrier family 5 member 5	Homo sapiens	62-65